BerGenBio

@BGenBio

We are a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL in aggressive diseases

Bergen, Norway / Oxford, UK
Vrijeme pridruživanja: prosinac 2016.

Tweetovi

Blokirali ste korisnika/cu @BGenBio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BGenBio

  1. Prikvačeni tweet
    18. kol 2019.

    BerGenBio ASA presents its results for the second quarter and first half 2019. Read the full release here:

    Poništi
  2. 4. velj

    Today we mark 2020 to honor the millions of people worldwide who have been affected by cancer

    Poništi
  3. 10. pro 2019.

    Thank you, , for organising yet another encouraging and insightful conference. See you again next year!

    Poništi
  4. 9. pro 2019.

    The presentation of updates from our Phase II trial with in combination with LDAC in elderly AML patients will be starting at 6pm in Hall B – come find us there!

    Poništi
  5. 9. pro 2019.

    We’re pleased to be attending the 61st conference this weekend! We will be presenting the latest data from our Phase II trial with in combination with LDAC in elderly AML patients on today at 6pm

    Poništi
  6. 10. stu 2019.

    Many thanks to the organisers for a fantastic . We’ve enjoyed a packed schedule and the opportunity to connect with friends old and new. See you next time!

    Poništi
  7. 8. stu 2019.

    BerGenBio presents latest data from Cohort A of the Phase II combination trial of and in . Come find us at the High Impact Clinical Trials session at the Prince George’s Exhibition Hall C at 5.10pm.

    Poništi
  8. 8. stu 2019.

    .’s Dr Matthew Krebs will be presenting the final data readout of the first cohort our Phase II trial of and in advanced . Come along to the High Impact Clinical Trials session this afternoon.

    Poništi
  9. 1. lis 2019.

    Thank you for a great conference and to all the attendees that made so worthwhile. See you again in 2020!

    Poništi
  10. 30. ruj 2019.

    Dr Straume is presenting a poster on our Phase Ib/II trial with in combination with /trametinib or in patients with metastatic melanoma. Presentation kicks off at 12pm in the poster area, Hall 4!

    Poništi
  11. 28. ruj 2019.

    At 12pm, Dr Jose M. Trigo Perez will present details of our Phase II trial of and in patients with advanced . Come find us in the poster area, Hall 4.

    Poništi
  12. 28. ruj 2019.

    Today we are presenting Phase II Trial Updates with Selective at the 2019 ESMO Congress. Come see us in the poster area, Hall 4 at 12 pm!

    Poništi
  13. 27. ruj 2019.

    We look forward to attending over the next few days in Barcelona! We will be presenting trial updates from our Phase II studies with selective . See you soon!

    Poništi
  14. 10. ruj 2019.

    Thank you for another outstanding conference this year, we look forward to the next one

    Poništi
  15. 10. ruj 2019.

    BerGenBio's CEO Richard Godfrey to Present at H.C. Wainwright 21st Annual Global Life Sciences Conference today. Full details are on our website here:

    Poništi
  16. 8. ruj 2019.

    Dr Enriqueta Felip presented a Mini Oral Session today at on our trial with and in patients with following chemotherapy

    Poništi
  17. 8. ruj 2019.

    Dr Enriqueta Felip presents a Mini Oral Session today in Colorado Springs (1994) at 11:05am on our trial with and in patients with following chemotherapy

    Poništi
  18. 7. ruj 2019.

    BerGenBio presents update of its Phase II trial of selective AXL inhibitor in at 2019 World Conference on Lung Cancer

    Poništi
  19. 6. ruj 2019.

    We’re looking forward to this year’s World Conference on Lung Cancer kicking off tomorrow. See you in Barcelona!

    Poništi
  20. proslijedio/la je Tweet
    20. kol 2019.

    Read our Lighthouse note on at , which covers the company's H119 results and the refinements to the clinical programme for its lead asset bemcentinib, the selective AXL inhibitor.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·